FDA lukewarm on PTC’s Translarna
admin 27th September 2017 Uncategorised 0Agency says studies into Duchenne muscular dystrophy drug were inconclusive More: FDA lukewarm on PTC’s Translarna Source: News
read more
Agency says studies into Duchenne muscular dystrophy drug were inconclusive More: FDA lukewarm on PTC’s Translarna Source: News
read moreBody warns of ‘public health crisis’ if move results in significant loss of staff More: EMA staff favour move to Amsterdam Source: News
read moreOpens new Bangalore office to bolster its global offering More: UK CRO Quanticate doubles its footprint in India Source: News
read moreEarlier this month, AstraZeneca rolled out positive results for a LAMA/LABA combo COPD med it hopes to bring to the U.S. market. And now, it’s followed up with positive results for another LAMA/LABA that could help the company gain a
read moreThe feds, which Friday extracted a guilty plea from Aegerion for paying kickbacks to get preferential treatment from a charity set up to help patients buy drugs, have expanded their probe into the charities themselves. More: DOJ looking closer at
read morePfizer last week sued Big Pharma peer Johnson & Johnson for “anticompetitive” contracting on blockbuster Remicade that’s limiting uptake of a discounted biosimilar. Now, taking its case straight to patients and the public, J&J says its exclusive contracts are not
read more© 1994 - 2026 B.M. Pharmaceuticals